SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 2.41 |
| Enterprise Value ($M) | -3.72 |
| Book Value ($M) | 6.18 |
| Book Value / Share | 2.10 |
| Price / Book | 0.39 |
| NCAV ($M) | 6.13 |
| NCAV / Share | 2.08 |
| Price / NCAV | 0.39 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -2.28 |
| Return on Assets (ROA) | -8.95 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.43 |
| Current Ratio | 3.43 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 8.66 |
| Assets | 8.70 |
| Liabilities | 2.52 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -14.90 |
| Net Income | -14.86 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -17.11 |
| Cash from Investing | -0.00 |
| Cash from Financing | 23.03 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Armistice Capital, Llc | 3.20 | 57.10 | |
| 13D | Cortice Biosciences, Inc. | 5.70 | ||
| 13G | Forster Robert | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 79,362 | 164,166 | 48.34 | |
| 138,979 | 291,825 | 47.62 | |
| 256,441 | 598,698 | 42.83 | |
| 40,667 | 107,304 | 37.90 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CLNN – Clene Inc. | CLRB – Cellectar Biosciences, Inc. |
| CMPX – Compass Therapeutics, Inc. | CNTX – Context Therapeutics Inc. |
| COCP – Cocrystal Pharma, Inc. |
Financial data and stock pages provided by
Fintel.io